These webinars are organised by the APSAD Smoking and Vaping Cessation Professionals (ASVCP) Special Interest Group for APSAD members, providing the opportunity to share information and knowledge through regular contact and webinars. The aim is the promotion of optimal smoking cessation practice in Australasia by trained health professionals incorporating evidence-based practice with an ongoing learning objective.
Membership of the ASVCP-SIG is open to APSAD members with an interest in Smoking and Vaping Cessation. For information contact Membership Services at This email address is being protected from spambots. You need JavaScript enabled to view it..
Coming Up in the ASVCP Webinar Series
Tuesday 4 June 2024 | 1300 (AEST)
Trends in vaping and tobacco smoking: An Australian and New Zealand outlook
Presenters:
Professor Hayden McRobbie, National Drug & Alcohol Research Centre, University of New South Wales, Sydney; and Regional Director, Northern National Public Health Service, Health New Zealand,
Dr Ryan Courntey, Program Lead Tobacco Research Group, NDARC, UNSW, Sydney; Associate Professor/ National Heart Foundation Future Leader Fellow; and ASVCP Chair
REGISTRATION WIL OPEN SHORTLY
Tuesday 18 June 2024 l 1200 (AEST)
An update on the Royal Australian College of General Practitioners (RACGP) guidance for clinicians on Therapeutic Vaping
Presenter: Dr Adam Pastor, Deputy Director Department Addiction Medicine, St Vincent's Hospital Melbourne
This webinar will cover the epidemiology and evidence base for treatment of tobacco use disorders in people with other substance use disorders. It will also cover important clinical considerations including drug-drug interactions and considerations in prioritisation of care..
|
Registration Terms and Conditions Any persons affiliated with tobacco entities (current, in the past, or have future plans), tobacco lobbyists, either professionally or on a personal basis, will be ineligible to attend or present at any APSAD webinar or event. APSAD’s policy is aligned with the World Health Organization’s Framework Convention on Tobacco Control, Article 5.3: There is a fundamental and irreconcilable conflict between the tobacco industry’s interest and public health policy interests. Registrations from such persons will be cancelled without notice. Paid registrations of such persons will not be refunded. |
|
Disclaimer The views expressed by presenters and speakers are not necessarily the views of APSAD, and the Society does not accept responsibility for any information, research, recommendation or advice presented. |
-----------------------------------------------------------------------------------------------
Watch ASVCP Webinars
Previous Recordings
April 2024 | An update on the Royal Australian College of General Practitioners (RACGP) guidance for clinicians on Therapeutic Vaping
This presentation will critique recent changes to regulation on access to vaping products and discuss use of therapeutic vaping for treatment of nicotine dependence.
Presenter: Professor Nicholas Zwar, Executive Dean, Faculty of Health Sciences and Medicine, Bond University
| WATCH THIS WEBINAR |
March 2024 | Reducing e-cigarette use among young people in NSW - social marketing campaign
This presentation will provide an overview of the NSW social marketing campaign to reduce e-cigarette use among young people (14-24 years). The presentation will focus on research and insights for campaign development
Presenters: Kate Reakes, Manager, Cancer Prevention, Cancer Screening & Prevention, Cancer Institute NSW, and Dr Sandra Rickards, Team Leader, Research & Evaluation, Cancer Screening & Prevention, Cancer Institute NSW
| WATCH THIS WEBINAR |
February 2024 | Intensive tobacco treatment incorporating contingency management for women attending substance use in pregnancy antenatal services. Is it feasible?
Pregnant women who use tobacco and other psychoactive substances are a high-priority group. Typically, considerable resources are devoted to preventing other substance use, but most women will continue to smoke tobacco throughout their pregnancy and beyond. This webinar describes the feasibility of an intensive tobacco treatment incorporating contingency management, nicotine replacement therapy and behavioural counselling into treatment for women attending substance use in pregnancy antenatal services. Included are results from the pilot trial including a cost-consequence analysis, and qualitative analysis of acceptability from the client and clinician perspective.
Presenter: Dr Melissa Jackson, Clinical Trial Coordinator, Drug and Alcohol Clinical Services Research Unit, Hunter New England Local Health District, NSW
| WATCH THIS WEBINAR |
- Prev
- Next >>